New drug combo shows promise for aggressive lymphoma
NCT ID NCT07662928
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding the drug epcoritamab to standard chemotherapy (DA-EPOCH-R) helps people with high-risk Burkitt lymphoma. About 43 adults will receive the combination. The study will check how many complete at least three cycles of treatment and track overall survival and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- epcoritamab plus chemotherapy (DA-EPOCH-R)
- What this could lead to
- If it works, this could offer a more effective treatment option for people with high-risk Burkitt lymphoma, potentially improving survival rates.
- What could go wrong
- This is an early phase 2 trial with only 43 participants, so results may not apply to everyone. The combination may cause serious side effects, and it's not yet known if it works better than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT BURKITT LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10021, United States